20109133

Source:http://linkedlifedata.com/resource/pubmed/id/20109133

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0086418, umls-concept:C0393022, umls-concept:C1832027
pubmed:issue	3
pubmed:dateCreated	2010-2-5
pubmed:abstractText	Since relapse of chronic lymphocytic leukemia (CLL), and refractoriness to treatment following relapse, is inevitable after initial treatment, development of novel treatment strategies is necessary.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101125414
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20, http://linkedlifedata.com/resource/pubmed/chemical/ofatumumab
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1744-7682
pubmed:author	pubmed-author:OsterborgAndersA
pubmed:issnType	Electronic
pubmed:volume	10
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	439-49
pubmed:meshHeading	pubmed-meshheading:20109133-Animals, pubmed-meshheading:20109133-Antibodies, Monoclonal, pubmed-meshheading:20109133-Antigens, CD20, pubmed-meshheading:20109133-Humans, pubmed-meshheading:20109133-Leukemia, Lymphocytic, Chronic, B-Cell
pubmed:year	2010
pubmed:articleTitle	Ofatumumab, a human anti-CD20 monoclonal antibody.
pubmed:affiliation	Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden. anders.osterborg@karolinska.se
pubmed:publicationType	Journal Article, Review, Research Support, Non-U.S. Gov't